Does erythropoietin protect the preterm brain?

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 89, Issue 4, 2004, Pages

  Strunk, T ^b   Hartel C ^b   Schultz, C ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN INJURY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HEALTH CENTER; HIGH RISK PATIENT; HUMAN; INFANT; NEUROPROTECTION; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; SIDE EFFECT; TREATMENT OUTCOME;

ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYPOXIA, BRAIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NEUROPROTECTIVE AGENTS;

EID: 3042718051     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2003.041533     Document Type: Article

References (56)

1. Wood NS, Marlow N, Costeloe K, et al. Neurologic and developmental disability after extremely preterm birth. N Engl J Med 2000;343:378-84.
2. Vannucci RC. Hypoxic-ischemic encephalopathy. Am J Perinatol 2000;17:113-20.
3. Berger R, Bender S, Sefkow S, et al. Peri/intraventricular hemorrhage: a cranial ultrasound study on 5286 neonates. Eur J Obstet Gynecol Reprod Biol 1997;75:191-203.
4. Yoon BH, Romero R Yang SH, et al. Interleukin-5 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. J Obstet Gynecol 1996;174:1433-40.
5. Schultz C, Temming P, Gembruch U, et al. Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants. Lancet 2002;359:1522-3.
6. Schultz C, Rott C, Temming P, et al. Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 2002;51:317-22.
7. Dammann O, Leviton A. Brain damage in preterm newborns: biological response modification as a strategy to reduce disabilities. J Pediatr 2000;136:433-8.
8. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002;438:36-42.
9. Vannucci RC, Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics 1997;100:1004-14.
10. Jelkmann W. The biology of erythropoietin. Clin Invest 1994;72:S3-10.
11. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:184-7.
12. Nagai A, Nakagawa E, Choi HB, et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001;60:386-92.
13. Juul SE, Anderson DK, Li Y, et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-9.
14. Juul SE, Yachnis AT, Rojiani AM, et al. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:148-58.
15. Sirén AL, Knerlich F, Poser W, et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271-6.
16. Maier RF, Bohme K, Dudenhausen JW, et al. Cord blood erythropoietin in relation to different markers of fetal hypoxia. Obstet Gynecol 1993;81:575-80.
17. Buescher U, Hertwig K, Wolf C, et al. Erythropoietin in amniotic fluid as a marker of chronic fetal hypoxia. Int J Gynaecol Obstet 1998;60:257-63.
18. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-B signalling cascades. Nature 2001;412:641-3.
19. Sirén AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Prac Natl Acad Sci USA 2001;98:4044-9.
20. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002;99:10659-64.
21. Genc S, Kuralay F, Genc K, et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett 2001;298:139-41.
22. Assandri R, Egger M, Gassmann M, et al. Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line. J Physiol 1999;516:343-52.
23. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, et al. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000;59:419-25.
24. Kristal B, Shurtz-Swirski R, Shasha SM, et al. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron 1999;81:406-13.
25. Sela S, Shurtz-Swirski R, Sharon R. The polymorphonuclear leukocyte: a new target for erythropoietin. Nephron 2001;88:205-10.
26. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
27. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
28. Yamaji R, Okada T, Moriya M, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996;239:494-500.
29. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemi damage. Proc Natl Acad Sci USA 1998;95:4635-40.
30. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643-51.
31. Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002;952:128-34.
32. Catania MA, Marciano MC, Parisi A, et al. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 2002;437:147-50.
33. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 2002;99:5627-31.
34. Springborg JB, Ma X, Rochat P, et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002;135:823-9.
35. Alafaci C, Salpietro F, Grasso G, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000;406:219-25.
36. Celik M, Gökmen N, Erbayraktar S, et al. Erythropoetin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002;99:2258-63.
37. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002;99:9450-5.
38. Ehrenreich H, Hasselblatt M, Dembowski, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
39. Maier RF, Obladen M, Scigalla P, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med 1994;330:1173-8.
40. Maier RF, Obladen M, Kattner E, et al. High- versus low-dose erythropoietin in extremely low birth weight infants. J Pediatr 1998;132:866-70.
41. Maier RF, Obladen M, Müller-Hansen I, et al. Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 2002;141:8-15.
42. Meyer MP, Meryer JH, Commerford A, et al. Recombinant human erythropoietin in the treatment of the anemai of prematurity: results of a double-blind, placebo-controlled study. Pediatrics 1994:918-23.
43. Shannon KM, Keith JF, Mentzner WC, et al. Recombinant human erythropoietin stimulate erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995;95:1-8.
44. Ohls K, Veerman MW, Christensen RD. The use of erythropoietin in neonates. Clin Perinatol 2000;3:681-96.
45. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108:934-42.
46. Ledbetter J, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 2000;35:178-82.
47. Juul SE, Harcum J, Li Y, et al. Erythropoietin is present in the cerebrospinal fluid of neonates. J Pediatr 1997;130:428-30.
48. Farrell F, Juul SE, Elliott C, et al. Erythropoietin crosses the blood brain barrier: an analysis in a non-human primate model. Blood 2001;98:148b.
49. Shingo T, Sorokan ST, Shimazaki T, et al. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-43.
50. Newton NR, Leonard CH, Piecuch RE, et al. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol 1999;19:403-6.
51. Soubasi V, Kremenopoulos GF, Diamanti E, et al. Follow-up of very low bith weight infants after erythropoietin treatment to prevent anemia of prematurity. J Pediatr 1995;127:291-7.
52. Ehrenkranz R, Ohls RK, DAS A, et al. Neurodevelopmental outcome and growth at 1822 months in extremely low birth weight infants treated with early erythropoietin and iron [abstract]. Pediatr Res 2002;51:291.
53. Ambrus JL, Ambrus CM, Dembinsky W, et al. Thromboembolic disease susceptibility related to red cell membrane fluidity in patients with polycythemia vera and effect of phlebotomies. J Med 1999;30:299-304.
54. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000;109:141-9.
55. Shibata J, Hasegawa J, Siemens HJ, et al. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood 2003;101:4416-22.
56. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.